




























	 Two	 stability‐indicating	 methods	 were	 developed	 and	 validated	 for	 the	 quantitativedetermination	of	 acemetacin	 (ACM)	 in	presence	of	 its	 degradation	products	 and	 impurities.
The	 first	 method	 was	 based	 on	 separation	 of	 ACM	 from	 its	 degradation	 products	 and
impurities	 by	 RP‐HPLC	 on	 Inertsil	 C8	 column	 (150	 ×	 4.6	 mm	 i.d)	 using	 a	 mobile	 phase
composed	 of	 0.02	M	 phosphate	 buffer:	 methanol	 (35:65,	 v:v,	 pH	 =	 6.5).	 The	 flow	 rate	 was
adjusted	 at	 1	mL/min	 and	 quantification	was	 achieved	with	UV	 detection	 at	 245	 nm	using
meloxicam	 as	 internal	 standard.	 The	 second	 method	 was	 based	 on	 multivariate	 spectro‐
photometric	analysis	using	partial	 least	square	regression	model.	The	drug	was	subjected	to
acid,	 base,	 oxidative	 and	 thermal	 stress	 conditions	 and	 the	 degradation	 products	 were
identified.	 The	 developed	 methods	 have	 the	 requisite	 accuracy,	 selectivity,	 sensitivity	 and
precision	to	assay	ACM	in	presence	of	its	degradation	products	and	impurities	either	in	bulk
powder	or	in	pharmaceutical	dosage	form.	The	results	obtained	for	the	analysis	of	ACM	in	its
pure	 form	 by	 the	 proposed	 methods	 were	 statistically	 compared	 to	 those	 obtained	 by
applying	 a	 reported	 HPLC	 method.	 The	 statistical	 comparison	 showed	 that	 there	 is	 no












Stability‐indicating	 methods	 provide	 useful	 information	
about	 the	 degradation	 pathways	 and	 degradation	 products	
that	 can	 be	 formed	 during	 storage.	 The	 information	 thus	
obtained	will	 facilitate	 pharmaceutical	 development	 in	 areas	







osteoarthritis,	 low	 back	 pain,	 postoperative	 pain	 and	
inflammation	 [1‐3].	 The	 efficacy	 of	 ACM	 is	 similar	 to	 that	 of	
indomethacin	in	the	treatment	of	inflammatory	and	rheumatic	
disorders	 but	 it	 is	 generally	 better	 tolerated	 than	 Indomet‐
hacin;	 in	 particular	 it	 produces	 fewer	 gastrointestinal	 side	
effects	[4‐9].		
Several	 methods	 have	 been	 reported	 for	 the	 analysis	 of	
ACM,	including	spectrophotometric	[10‐14],	chromatographic	
[12,14‐26]	 and	 electrochemical	 methods	 [27‐29]	 for	 the	
determination	 of	 ACM	 either	 alone	 or	 in	 combination	 with	
other	 NSAIDs	 in	 biological	 fluids	 and	 pharmaceutical	
formulations.	 Stability	 indicating	 HPTLC	 and	 spectrophoto‐








unique	 in	 possessing	 almost	 universal	 applicability	 and	
remarkable	 assay	 precision.	 Chemometrics	 is	 a	 chemical	
discipline	that	uses	mathematics,	statistics	and	formal	logic	to	
design	or	select	optimal	experimental	procedures,	 to	provide	





reported	 for	 the	 determination	 of	 ACM	 in	 presence	 of	 its	
degradation	products	and	impurities.	Consequently,	the	aim	of	
the	 present	 work	 was	 to	 develop	 fast,	 simple	 and	 accurate	
methods	 for	 the	assay	of	ACM	 in	presence	of	 its	degradation	
products	and	 impurities.	Moreover,	 the	degradation	products	









HPLC	 analysis	 was	 performed	 using	 Agilent	 HPLC	
instrument	 (1100	 series)	 Japan,	 equipped	 with	 an	 isocratic	
pump	 model	 G1310A,	 connected	 with	 a	 UV	 detector	 model	
G1314A.	The	injector	was	a	manual	Rheodyne	injector	(Model	
G1328B,	USA)	equipped	with	a	20	µL	injector	 loop	and	a	100	
µL	Agilent	 syringe.	The	 instrument	was	connected	 to	an	 IBM	
compatible	 PC	 bundled	with	 Agilent	 Chemstation	 Chromato‐
graphy	data	station	software	HPLC	septum	manager	and	an	HP	
5700	Deskjet	printer.	pH	meter	(Jenway‐3510,	UK).	Sonicator	





Measurements	 were	 carried	 out	 on	 a	 Shimadzu	 1650	
double	 beam	 UV‐PC	 spectrophotometer	 connected	 to	 a	
computer	 loaded	 with	 Shimadzu	 software	 UV	 probe	 2.10,	
(Hiroshima,	 Japan).	 UV	 spectra	 were	 recorded	 using	 a	 1	 cm	
quartz	cell.	Scans	were	carried	out	in	the	range	of	200‐400	nm	










City,	Cairo,	Egypt	and	 it	was	certified	 to	 contain	99.92%	w:w	
according	 to	 the	 manufacturer’s	 method.	 Indomethacin	
standard	material	was	supplied	by	AUG	Pharma,	6th	Industrial	
Zone,	6	October	City,	Egypt.	Meloxicam	standard	material	was	
supplied	by	Misr	Pharmaceutical	 Industries,	 92	Matareya	 St.,	
El	Matareya,	Cairo,	Egypt.	p‐Chlorobenzoic	 acid	was	 supplied	
by	 Merck‐Schuchardt,	 Dr.	 Tu.	 Schuchardt	 &	 Co.	 D‐85662,	













All	 chemicals	 and	 reagents	 used	 throughout	 this	 work	
were	 of	 analytical	 grade	 and	 solvents	 were	 of	 HPLC	 grade:	
Sodium	 hydroxide	 (Adwic,	 Egypt),	 potassium	 dihydrogen	
phosphate	 (Adwic,	 Egypt),	 o‐phosphoric	 acid	 (Adwic,	 Egypt),	
hydro‐chloric	 acid	 (Sigma‐Aldrich,	 Germany),	 hydrogen	







(100	µg/mL)	was	prepared	by	 accurately	weighing	 10	mg	 of	
ACM	into	100	mL	volumetric	flask,	dissolve	in	and	complete	to	
volume	with	methanol.		
Indomethacin	 stock	 standard	 solution:	 Indomethacin	
standard	 solution	 (100	 µg/mL)	 was	 prepared	 by	 accurately	
weighing	10	mg	of	indomethacin	into	100	mL	volumetric	flask,	
dissolve	in	and	complete	to	volume	with	methanol.	





standard	 solution	 (100	 µg/mL)	 was	 prepared	 by	 accurately	
weighing	10	mg	of	PCBA	into	100	mL	volumetric	flask,	dissolve	
in	and	complete	to	volume	with	methanol.	
5‐Methoxy‐2‐methyl‐3‐indole	 acetic	 acid	 stock	 standard	













flask.	 The	 volume	 was	 then	 completed	 using	 methanol	 to	
produce	 concentration	 equivalent	 to	 100	 µg/mL.	 The	 degra‐









refluxed	 for	 3	 hours	 in	 boiling	water	 bath.	 The	 solution	was	
neutralized	with	0.1	N	NaOH,	transferred	quantitatively	to	100	
mL	volumetric	flask	and	completed	to	volume	using	methanol	











and	 completed	 to	 volume	 with	 methanol	 to	 give	 final	
concentration	 equivalent	 to	 100	 µg/mL.	 The	 degradation	
process	 was	 followed	 every	 15	 minutes	 by	 HPLC	 using	











equivalent	 to	 100	 μg/mL.	 The	 degradation	 process	 was	













adjusted	with	 the	mobile	 phase.	 An	 aliquot	 of	 20	 µL	 of	 each	






















The	 previously	 mentioned	 ACM	 concentrations	 under	
repeatability	were	analyzed	 in	 triplicates	on	 three	 successive	





Robustness	 of	 the	 method	 was	 tested	 by	 applying	
deliberate	 variations	 in	 flow	 rate,	 pH	 of	mobile	 phase	 buffer	





System	 suitability	 was	 checked	 by	 calculating	 different	







For	 the	 construction	 of	 calibration	 and	 validation	 sets,	
twenty	 five	 mixtures	 of	 ACM,	 indomethacin,	 PCBA	 and	 5‐
methoxy‐2‐methyl‐3‐indole	acetic	acid	in	different	ratios	were	
prepared	 using	 five	 level	 four	 factor	 experimental	 design	
where	 different	 volumes	 were	 transferred	 from	 their	
corresponding	stock	solutions	(100	µg/mL)	into	a	series	of	10	
mL	 volumetric	 flasks	 and	 the	 volumes	were	 completed	with	
0.01	N	HCl.	From	this	mixed	set,	eight	samples	were	randomly	
chosen	 and	 used	 for	 external	 validation	 (validation	 set)	 and	






The	 absorption	 spectra	 of	 calibration	 and	 validation	







Ten	 capsules	 (labeled	 to	 contain	 60	 mg	 ACM)	 were	
emptied	 and	 accurately	 weighed.	 An	 accurate	 weight	
equivalent	 to	 10	 mg	 ACM	 was	 transferred	 into	 a	 100	 mL	




mL)	 was	 transferred	 into	 a	 10	 mL	 volumetric	 flask	 and	 the	
volume	 was	 completed	 with	 the	 mobile	 phase	 for	 HPLC	
method	and	with	0.01	N	HCl	for	the	PLS	chemometric	method	
to	produce	solutions	of	concentrations	equivalent	to	10	µg/mL	
of	 ACM.	 The	 procedure	 was	 completed	 as	 described	 under	
calibration	step.	 For	HPLC	method,	 the	concentration	of	ACM	
was	 calculated	 from	 the	 corresponding	 regression	 equation.	
For	PLS	model,	the	zero‐order	spectra	of	the	prepared	solution	
were	recorded	in	the	range	of	200‐400	nm.	Then	the	recorded	







boiling	 water	 bath),	 basic	 (0.1	 N	 NaOH	 for	 30	 min	 at	 room	
temperature),	 oxidative	 (3%	 H2O2	 for	 3	 hours	 at	 room	
temperature)	 and	 thermal	 stress	 conditions	 (140	 °C	 for	 3	
hours).	
The	 degradation	 process	 was	 monitored	 by	 HPLC	 (C8	




under	 mild	 conditions	 giving	 two	 degradation	 products.	 In	
acidic	conditions,	ACM	is	degraded	but	under	stress	conditions	








of	 the	 amide	 and	 the	 ester	 linkages	 giving	 two	 degradation	
products.	 By	 reviewing	 the	 reported	 stability‐indicating	
methods	 for	 indomethacin	 [35‐37]	 which	 possesses	 almost	
similar	 structure	 to	 ACM,	 the	 expected	 degradation	 products	
were	 p‐chlorobenzoic	 acid	 and	 5‐methoxy‐2‐methyl‐3‐indole	
acetic	 acid.	 Consequently,	 standard	 solutions	 of	 the	 expected	
degradation	 products	 were	 prepared	 and	 injected	 under	 the	
same	 chromatographic	 conditions.	 Elution	 of	 the	 standard	
solutions	at	the	same	retention	times	confirmed	the	presence	
of	 p‐chlorobenzoic	 (PCBA)	 acid	 and	 5‐methoxy‐2‐methyl‐3‐
indole	acetic	acid	as	degradation	products	under	both	alkaline	
and	 acidic	 stress	 conditions.	 Indomethacin	 appeared	 as	 an	
intermediate	degradation	product	in	acid	hydrolysis,	Figure	3.	













min),	 (b)	 HPLC	 chromatogram	 of	 alkaline‐induced	 degradation	 products	
equivalent	to	10	µg/mL	(tR	=	2.109	and	2.720	min),	(c)	HPLC	chromatogram	
of	 acid‐induced	 degradation	 products	 equivalent	 to	 10	 µg/mL	 (tR	 =	 2.104	
and	2.705	min).	
	
PCBA	 is	 also	 a	 degradation	 product	 and	 a	 minor	
metabolite,	 while	 indomethacin	 is	 considered	 as	 a	 major	
metabolite	 [39].	 Furthermore,	 indomethacin	 is	 used	 as	 an	
intermediate	in	the	synthesis	of	ACM	[40],	which	represents	a	
valuable	 modification	 of	 indomethacin	 due	 to	 its	 better	
tolerability	 and	 less	 gastric	 damage	 [41,42].	 Hence,	 it’s	
important	to	detect	the	presence	of	indomethacin	as	impurity.		
Finally,	 by	 applying	 the	 chromatographic	 conditions	
mentioned	 above,	 it	 was	 possible	 to	 determine	 ACM	 in	 the	













the	 retention	 times	 was	 investigated.	 Different	 ratios	 of	
methanol	were	tried	in	the	range	of	60‐90%.	It	was	found	that	
methanol	 in	 the	ratio	of	65%	was	optimum	for	separation	as	
lowering	 the	 ratio	 of	 methanol	 below	 65%	 resulted	 in	 very	
high	retention	times	and	increasing	the	methanol	ratio	above	






6.5.	 The	 low	pH	values	 resulted	 in	 faster	 elution	but	 showed	
overlap	between	the	peaks	of	ACM	and	indomethacin.	Besides,	
the	reported	pka	values	for	ACM	(pKa	=	2.9)	and	Indomethacin	





Upon	 trying	 different	 buffers	 as	 phosphate	 and	 acetate	









Figure	 3.	 (a) HPLC	 chromatogram	 of	 standard	 p‐chlorobenzoic	 acid	 10	
µg/mL	(tR	=	2.708	min),	(b)	HPLC	chromatogram	of	standard	5‐methoxy‐2‐

















Figure	 4.	 HPLC	 chromatogram	 of	 a	 resolved	 mixture	 of	 10	 µg/mL	 of	 p‐
chlorobenzoic	 acid	 (tR	 =	 2.672),	 and	 10	 µg/mL	 of	 5‐methoxy‐2‐methyl‐3‐
indole	 acetic	 acid	 (tR	 =	 2.096),	 10	 µg/mL	 of	 meloxicam	 (tR	 =	 3.105),	 10	




By	changing	 the	wavelength	 to	254	nm,	 the	sensitivity	 to	
the	degradation	products	was	reduced.	Finally	by	adjusting	the	








Calibration	 curves	 were	 constructed	 by	 plotting	 the	 relative	
peak	areas	 against	 the	corresponding	concentrations	and	 the	
regression	 equations	 were	 computed.	 The	 method	 was	
validated	 as	 per	 the	 ICH	 [44]	 guidelines.	 The	 regression	 and	
validation	 parameters	 of	 the	 proposed	 method	 are	
summarized	 in	 Table	 1.	 System	 suitability	 was	 checked	 by	
calculating	different	parameters	such	as	capacity	factor,	tailing	
factor,	column	efficiency	(N),	selectivity	and	resolution	factors,	
where	 the	 system	 was	 found	 to	 be	 suitable	 relative	 to	 the	
reference	values	[45]	as	shown	in	Table	2.		The	accuracy	of	the	
proposed	 HPLC	 method	 was	 assessed	 by	 analyzing	 five	
different	 concentrations	 of	 ACM	 in	 its	 pure	 form	 and	
calculating	 its	 concentration	 from	 the	 obtained	 regression	
equation.	 The	 percentage	 recoveries,	 mean	 recovery	 and	
relative	standard	deviation	were	then	calculated,	Table	3.		
	



















The	 absorption	 spectra	 of	 ACM,	 its	 degradation	 products	
and	 impurities	 (Indomethacin,	 PCBA,	 5‐methoxy‐2‐methyl‐3‐
indole	 acetic	 acid)	 are	 shown	 in	Figure	5.	ACM	and	 indomet‐
hacin	show	almost	similar	spectral	features,	which	hinders	the	
determination	 of	 ACM	 in	 presence	 of	 indomethacin	 by	
univariate	 spectrophotometric	 methods.	 Thus,	 multivariate	
PLS	 regression	 model	 was	 applied	 which	 enabled	 the	
determination	of	ACM	in	presence	of	 indomethacin	as	well	as	
PCBA	 and	 5‐methoxy‐2‐methyl‐3‐indole	 acetic	 acid	 in	 their	




Figure	 5. Absorption	 spectra	 of	 10	 µg/mL	 of	 each	 of	 acemetacin,	









PCBA	 Indomethacin	 Acemetacin	 Limit	
Retention	time	(tR)	 2.096	 2.672 8.392 9.729 	
Resolution	(R)	 	 3.430 15.24 2.610 Rs	>	1.5	
Tailing	factor	(T)	 1.100	 1.500 0.875 0.944 T	≤	2	
Capacity	factor	(K')	 	 	 4.000	 4.830	 K'	>	2	
Selectivity	factor	(α)	 	 	 	 1.207	 α	>	1	
Column	efficiency	(N)	 2458	 4096 5098 4959 N	>	2000	
Height	equivalent	to	theoretical	plate	
(HETP)	

















Table	4.	 Concentrations	 of	 acemetacin,	 indomethacin,	p‐chlorobenzoic	 acid	 and	 5‐methoxy‐2‐methyl‐3‐indole	 acetic	 acid	 in	 the	 calibration	 and	 validation						
sets	*.	
Sample	no	 Acemetacin	(µg/mL)	 Indomethacin	(µg/mL) p‐Chlorobenzoic	acid (µg/mL) 5‐Methoxy‐2‐methyl‐3‐indole	acetic	acid	(µg/mL)
1	 16	 3.2	 2.0 6.0
2	 16	 1.6	 1.0	 9.0	
3	 8	 1.6	 3.0	 4.5	
4	 8	 4.8	 1.5	 9.0	
5	 24	 2.4	 3.0 6.0
6	 12	 4.8	 2.0 4.5
7	 24	 3.2	 1.5 4.5
8	 16	 2.4	 1.5 7.5
9	 12	 2.4	 2.5 9.0
10	 12	 4.0	 3.0 7.5
11	 20	 4.8	 2.5	 6.0	
12	 24	 4.0	 2.0	 9.0	
13	 20	 3.2	 3.0	 9.0	
14	 16	 4.8	 3.0 3.0
15	 24	 4.8	 1.0	 7.5	
16	 24	 1.6	 2.5 3.0
17	 8	 4.0	 1.0 6.0
18	 20	 1.6	 2.0 7.5
19	 8	 3.2	 2.5 7.5
20	 16	 4.0	 2.5 4.5
21	 20	 4.0	 1.5 3.0
22	 20	 2.4	 1.0	 4.5	
23	 12	 1.6	 1.5 6.0
24	 8	 2.4	 2.0	 3.0	















400	 nm	 with	 0.1	 nm	 intervals,	 thus	 producing	 1302	 data	
points	per	spectrum.	The	produced	spectral	data	matrix	has	25	
rows	 representing	 different	 samples	 and	 1302	 columns	
representing	 wavelengths	 (25	 ×	 1302).	 Seventeen	 samples	
were	randomly	chosen	and	used	for	calibration	and	eight	were	
used	as	an	external	validation	set.	The	concentrations	of	ACM,	
indomethacin,	 PCBA	 and	 5‐methoxy‐2‐methyl‐3‐indole	 acetic	
acid	 in	 each	mixture	are	 shown	 in	Table	4.	 In	 order	 to	 apply	
PLS	 model	 to	 the	 data,	 random	 subsets	 were	 applied	 as	 an	
internal	cross	validation	method	[46].	To	choose	the	optimum	
number	 of	 LVs,	 F‐statistics	 [47]	 was	 used	 in	 which	 the	 root	




In	 order	 to	 assess	 the	predictive	 ability	 of	 the	 developed	
model,	 it	 was	 applied	 to	 an	 external	 validation	 set	 for	 the	
determination	of	ACM.	Calibration	graphs	were	constructed	by	
plotting	 the	 predicted	 concentrations	 for	 ACM	 by	 the	 deve‐
loped	 model	 versus	 the	 true	 concentrations.	 The	 statistical	
parameters	 of	 the	 linear	 relationship	 between	 the	 calculated	
and	 the	 true	 concentrations	 of	 ACM	 in	 the	 validation	 set	 are	











1	 12.00	 12.25 102.08
2	 24.00	 23.51 97.96
3	 24.00	 24.14 100.58
4	 20.00	 19.34	 96.70	
5	 8.00	 7.94	 99.25	
6	 16.00	 15.85 99.06
7	 8.00	 8.04	 100.50	












10.00	 10.14 101.40 10.00 10.04	 100.40
10.04	 100.40	 10.06	 100.60	
10.09 100.90 10.13	 101.30
Mean	 100.90	 Mean	 100.77	




Parameter	 HPLC	method	 PLS	model	 Reported	HPLC	method	**	
Mean	 100.15	 99.40 99.39
SD	 0.995	 1.664 1.013
n	 8	 8	 8	
Variance	 0.990	 2.770 1.026
Student’s	t‐test	 1.521	(2.145)	*	 0.014	(2.179)	*	 	







as	a	function	of	 the	number	of	 latent	variables	(LVs)	used	to	construct	 the	
PLS	model.	
	
The	 proposed	methods	were	 successfully	 applied	 for	 the	
determination	 of	 ACM	 in	 Ost‐Map®	 capsules	 with	 good	
recoveries,	Table	7.	
The	 results	 obtained	 by	 the	 proposed	 methods	 were	
statistically	 compared	 to	 those	 obtained	 by	 applying	 the	
reported	HPLC	method	 [24]	and	no	significant	difference	has	




The	 suggested	 methods	 are	 simple,	 accurate	 and	 rapid.	
Application	of	the	proposed	method	to	the	analysis	of	ACM	in	
the	 presence	 of	 its	 degradation	 products,	 impurities	 and	 in	
pharmaceutical	 formulations	 showed	 that	 neither	 the	
degradation	products,	 impurities	 nor	 the	 excipients	 interfere	
with	 the	determination	of	 ACM,	 indicating	 that	 the	 proposed	
method	 could	 be	 applied	 as	 a	 stability	 indicating	 one.	 The	
proposed	methods	are	simple	precise	and	could	be	applied	in	
quality	 control	 laboratories	 for	 the	 routine	 analysis	 of	 the	
studied	 drug	 either	 in	 bulk	 powder	 or	 in	 pharmaceutical	
dosage	form.	
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